296.87MMarket Cap-4.67P/E (TTM)
4.800High4.225Low1.03MVolume4.440Open4.380Pre Close4.69MTurnover2.29%Turnover RatioLossP/E (Static)64.26MShares10.00052wk High23.94P/B208.63MFloat Cap1.30052wk Low--Dividend TTM45.16MShs Float22.137Historical High--Div YieldTTM13.13%Amplitude0.607Historical Low4.537Avg Price1Lot Size
Corvus Pharmaceuticals Stock Forum
Corvus Pharmaceuticals Inc - Data Show Favorable Safety and Efficacy Profile
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Monday, 13th January at 7:30 am
BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with m...
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha
why everyone are leaving? i thought this is a promising clinical sign???
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...
📊⚡️📊
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe ...
No comment yet